Stokes Pharmacy is proud to partner with Anivive Lifesciences to make precision medicine more accessible to veterinarians.
Through Anivive’s SearchLight DNA™ next generation sequencing test, veterinarians can identify mutations in 120 relevant cancer genes to aid in the diagnosis and prognosis of cancer and inform treatment decisions.
This collaboration brings together Anivive’s advanced diagnostics and Stokes Pharmacy’s trusted expertise in veterinary compounding to give clinicians powerful tools in the fight against canine cancer.
You can submit biopsy and cytology samples directly to the Vidium Lab for histopathology and/or cytology as well as SearchLight DNA™ testing or we can obtain samples from your laboratory for evaluation.
Once your samples are received, DNA will be extracted and sequenced to identify unique mutations.
Vidium will analyze tumor mutations and match them against Vidium Insight, a proprietary biomarker database.
A detailed report will be created, outlining tumor mutations along with a list of targeted therapeutic drug(s), if the patient’s tumor or mutations are a match for an existing drug.
Access your results in 9-12 days securely through the Anivive portal. Experts are ready to help interpret the findings and discuss treatment options.
Use these genomic insights to guide personalized treatment plans, including targeted therapies available from Stokes Pharmacy.
New lower pricing on targeted therapies!
Cancer is one of the leading causes of death in dogs, and traditional treatment options are often limited. By combining cutting-edge genetic testing with precisely targeted medications, veterinarians now have the tools to offer more personalized and potentially more effective therapies.
Stokes Pharmacy and Anivive are committed to advancing veterinary oncology and supporting veterinarians in delivering compassionate, evidence-based cancer care.
